Apnimed IPO expected to price in top half of range - report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts APMD Hot Sheet
Join SI Premium – FREE
Investing.com -- Apnimed Inc. expects its initial public offering to price in the top half of the $14 to $16 marketing range, Bloomberg reported Thursday.
The sleep-related breathing disease drug developer has received demand for multiple times the available shares and has drawn large orders from long-only investors, according to the report.
The company is on track to price later Thursday, the report said.
Bank of America Corp, Evercore Inc, Cantor Fitzgerald and LifeSci Capital are working on the offering.
Shares are expected to begin trading on the Nasdaq Global Market on Friday under the symbol APMD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seagate stock rises on analyst price target upgrades
- EchoStar gains on analyst optimism
- OpenAI expands ChatGPT ads to 26 more countries
Create E-mail Alert Related Categories
InvestingRelated Entities
Cantor Fitzgerald, IPO, Maynard Um, Mark Zuckerberg, BofA/Merrill Lynch, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
